MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Viemed Healthcare Cost of Revenue 2011-2026 | VMD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Viemed Healthcare
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 70.2 M | 54.2 M | 43.7 M | 51.2 M | 24.2 M | 16.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70.2 M | 16.7 M | 43.4 M |
Quarterly Cost of Revenue Viemed Healthcare
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.6 M | 26.3 M | 25.8 M | - | 23.6 M | 22.1 M | 20.8 M | - | 18.8 M | 17.2 M | 15.6 M | - | 14.1 M | 12.9 M | 12.5 M | - | 10.9 M | 9.77 M | 10.7 M | - | 14 M | 16.9 M | 8.25 M | - | 6.32 M | 5.69 M | 5.04 M | 4.84 M | 4.1 M | 4.18 M | 3.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.6 M | 3.56 M | 13.8 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
13.7 M | - | 1.37 % | $ 20.5 M |  USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 39.54 | 0.69 % | $ 5.89 K | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 7.94 | 1.53 % | $ 570 M |  Israel |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 9.56 | 1.7 % | $ 1.29 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.0 | 0.25 % | $ 149 M |  France |
 |
CONMED Corporation
CNMD
|
624 M | $ 43.17 | -0.33 % | $ 1.34 B | USA |
 |
Electromed
ELMD
|
14 M | $ 23.98 | 0.25 % | $ 203 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 29.57 | -0.89 % | $ 1.36 B | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.28 | 3.48 % | $ 114 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.52 | -1.44 % | $ 53.4 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.77 | -3.91 % | $ 41.9 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 183.24 | 0.33 % | $ 13.7 B | USA |
 |
Inari Medical
NARI
|
44.5 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 3.91 | 5.68 % | $ 828 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 112.45 | -0.99 % | $ 196 B | USA |
 |
NuVasive
NUVA
|
337 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 72.23 | -2.19 % | $ 107 B | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.1 | 5.81 % | $ 1.28 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 12.81 | -1.61 % | $ 1.92 B | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.5 | -0.74 % | $ 873 M | Israel |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.43 | - | $ 23.1 M | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 104.42 | 0.12 % | $ 1.32 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 84.58 | -0.8 % | $ 49.5 B | USA |